Obinutuzumab and Liso-Cel Revisions to CLL/SLL NCCN Guidelines Mark Most Notable Changes of 2024
Matthew Cortese, MD, MPH, details 2024/2025 updates to the NCCN guidelines for CLL/SLL and treatments to look forward to in the future.
Related Articles
Perioperative Durvalumab Plus Chemotherapy Represents the Future of Personalized NSCLC Care
Mark Awad, MD, PhD, and Jonathan Spicer, MD, PhD, discuss the FDA approval of perioperative durvalumab for patients with resectable NSCLC.
The San Antonio Breast Cancer Symposium: SABCS® Hotels
“An international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer.” The San Antonio Breast Cancer Symposium is presented by…
Report on Artificial Intelligence and Health Insurance – Consumer Health Reps at NAIC
This report was compiled by NORC at the University of Chicago on behalf of the Consumer Representatives to the NAIC. The report examines the current…
Friends Annual Meeting 2024 Recap: Sharing Next Steps and Opportunities with Advocates – Friends of Cancer Research
Friends Annual Meeting 2024 Recap: Sharing Next Steps and Opportunities with Advocates Thursday, December 5, 2024 12PM – 1PM ET Location: Virtual (Zoom) Webinar will…
Comparing Dosing Schedules With Standard Therapies
Joshua K. Sabari, MD, discusses how the dosing schedule of ifinatamab deruxtecan offers advantages in terms of simplicity and treatment adherence vs topotecan and lurbinectedin,…
What will Trump’s return to the White House mean for oncology? “Our work just got a lot more difficult.” – The Cancer Letter
On Nov. 5, as the American people expressed their will, electing Donald Trump to a second term, I started to wonder what my friends in…
Supplemental Data on the Efficacy of Fenfluramine to Treat Dravet Syndrome-Associated Seizures
Kelly Knupp, MD, discusses supplemental data on the efficacy of fenfluramine in treating Dravet syndrome-associated seizures.
Clinical Trial Evaluating Investigational AVB-101 in Patients With FTD
James “Brad” Elder, MD, discusses a clinical trial evaluating the investigational gene therapy, AVB-101 in patients with FTD.
Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial
Adding HIPEC to cytoreductive surgery after response to platinum-based chemotherapy at first epithelial ovarian cancer recurrence significantly improved overall survival. When treating patients with late…
